866030-35-5

Basic information

• Product Name: [(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S, 4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic Acid 1,1-tert-Butyl Ester
• Synonyms: [(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S, 4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic Acid 1,1-tert-Butyl Ester;[(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S,4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic acid tert-butyl ester;CarbaMic acid, [(1S,3S)-3-[[4-Methoxy-3-(3-Methoxypropoxy)phenyl]Methyl]-4-Methyl-1-[(2S,4S)-tetrahydro-4-(1-Methylethyl)-5-oxo-2-furanyl]pentyl]-, 1,1-diMethylethyl ester;(-)-Boc-Lactone: 5(S)-{l(S)-(tert-Butoxycarbonyl)aMino-3(S)-[4-Methoxy-3-(3-Methoxypropoxy)-benzyl]-4-Mthyl-pentyl}-3(S)-isopropyl-tetrahydrofuran-2-one;N-[(1S,3S)-3-[[4-Methoxy-3-(3-Methoxypropoxy)phenyl]Methyl]-4-Methyl-1-[(2S, 4S)-tetrahydro-4-(1-Methylethyl)-5-oxo-2-furanyl]pentyl]carbaMic Acid 1,1-DiMethylethyl Ester;InterMediate of Aliskiren;[(1S,3S)-3-[[4-Methoxy-3-(3-Methoxypropoxy)phenyl]Methyl]-4-Methyl-1-[(2S,4S)-tetrahydro-4-(1-Methylethyl)-5-oxo-2-furanyl]pentyl]-, 1,1-diMethylethyl ester CarbaMic acid;tert
• CAS NO: 866030-35-5
• Molecular Formula: C₃₀H₄₉NO₇
• Molecular Weight: 535.71256
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 866030-35-5.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 650.438 °C at 760 mmHg
• Flash Point: 347.172 °C
• Appearance: /
• Density: 1.057
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane, Methanol
• PKA: 11.81±0.46(Predicted)
• CAS DataBase Reference: [(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S, 4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic Acid 1,1-tert-Butyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S, 4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic Acid 1,1-tert-Butyl Ester(866030-35-5)
• EPA Substance Registry System: [(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S, 4S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamic Acid 1,1-tert-Butyl Ester(866030-35-5)

Safety Data

• Hazardous Substances Data: 866030-35-5(Hazardous Substances Data)

Usage

Uses

Intermediate in the preparation of Aliskiren.

Upstream product

• 866030-34-4 ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-((S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl)-5-methyl-hexyl)-carbamic acid tert-butyl ester 
• 900811-48-5 (5S)-dihydro-5-[(1S,3S)-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-aminopentyl]-3-(1-methylethyl)-2(3H)-furanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 900811-40-7 methyl (2S,4S)-2-[[(phenylmethoxy)carbonyl]amino]-4-methoxy-3-(3-methoxypropoxy)-γ-(1-methylethyl)benzenepentanoate 
• 900811-41-8 (2S,4S)-2-[[(phenylmethoxy)carbonyl]amino]-4-methoxy-3-(3-methoxypropoxy)-γ-(1-methylethyl)benzenepentanoic acid 
• 900811-45-2 phenylmethyl [(1S,3S)-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S)-tetrahydro-5-oxo-2-furanyl]pentyl]carbamate 
• 900811-43-0 (5S,7S)-5-Benzyloxycarbonylamino-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-4-oxo-nonanoic acid methyl ester 
• 900811-42-9 pyridin-4-yl (2S,4S)-2-[[(phenylmethoxy)carbonyl]amino]-4-methoxy-3-(3-methoxypropoxy)-γ-(1-methylethyl)benzenepentanethioate 
• 900811-49-6 {(1S,3S)-1-((S)-4-Isopropylidene-5-oxo-tetrahydro-furan-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester 
• 172900-69-5 (R)-4-(2-(bromomethyl)-3-methylbutyl)-1-methoxy-2-(3-methoxypropoxy)benzene 
• 656241-36-0 methyl (2S,4S)-2-amino-4-[4-methoxy-3-(3-methoxypropoxy)benzyl]-5-methylhexanoate 
• 656241-17-7 (2S,5R)-2,5-dihydro-3,6-dimethoxy-2-{(2S)-2-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-3-methylbutyl}-5-(1-methylethyl)pyrazine 
• 172900-83-3 (1S,3S)-{1-formyl-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid tert-butyl ester 
• 866030-33-3 (2R,5S)-3,6-diethoxy-2-isopropyl-5-((S)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-2,5-dihydropyrazine 

Downstream Products

• 173338-07-3 tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate 
• 173337-63-8 (1S,2S,4S,2'S)-(4-butylcarbamoyl-2-hydroxy-1-{2'-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl}-5-methylhexyl)carbamic acid tert-butyl ester 
• 1013922-76-3 tert-butyl [(1S,2S,4S)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl}-5-methyl-4-(2-nitrooxyethylcarbamoyl)hexyl]carbamate 
• 173334-57-1 (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide 
• 934841-35-7 C₃₀H₅₀NO₈^(1-)*Li⁽¹⁺⁾ 
• 1243342-34-8 C₃₅H₆₂N₂O₇ 
• 1243342-32-6 C₃₆H₆₄N₂O₇ 
• 1243342-36-0 C₃₆H₆₂N₂O₇ 
• 853273-53-7 ((1S,2S,4S)-4-benzylcarbamoyl-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl}-5-methyl-hexyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Aliskiren intermediate preparation method

The present invention relates to the technical field of pharmaceutical preparation method, the preparation method of the existing long reaction time, the problem of low yield, provides a aliskiren preparation method, comprises the following steps: S1, 1st intermediate preparation: the raw material is dissolved in a solvent, adding sodium hypochlorite and sodium bisulfite reaction, shall be 1st intermediate; S2, intermediate in the preparation of 2nd: to the 1st intermediate dropping 4 - bromo - 1 - methoxy - 2 - (3 - methoxy third oxygen radical) benzene, tetrahydrofuran solution, adding low [...] catalyst, to obtain the 2nd intermediate; S3, aliskiren intermediate preparation: will be soluble in ethyl acetate in the 2nd intermediate, then adding water, nitrogen replacement 3 times, the hydrogen replaced 3 times after adding the hydrogen hydrogenation reaction, to obtain the product. By adding low deuterium water as a catalyst, help to accelerate the step S2 of the reaction rate, the reaction time is shortened, while at the same time help to improve the step S2 in the reaction yield, and then make the total reaction yield can be improved.

A stereoselective catalytic nitroaldol reaction as the key step in a strategy for the synthesis of the renin inhibitor aliskiren

Aliskiren is the first-in-class orally active direct renin inhibitor. It was approved in 2007 for the treatment of hypertension. We have designed a new strategy for the convergent synthesis of aliskiren that involves a catalytic stereoselective nitroaldol reaction as the key step. A new enantiopure nitroalkane (synthon A1), prepared in only three steps from a commercially available enantiopure 2-(arylmethyl)-3-methyl butanol derivative, was successfully used in a copper-catalysed Henry reaction to give a nitrolactone intermediate in which the correct configuration for the final product was established at all four stereocentres. Nitro-group reduction, Boc-protection of the resulting amine, aminolysis of the lactone with 3-amino-2,2-dimethylpropionamide, and finally Boc-deprotection led to the enantiopure renin inhibitor aliskiren.

PROCESS FOR THE PREPARATION OF ALISKIREN

The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.